PVLA Palvella Therapeutics, Inc.
$150.13▼ -0.17%
Healthcare
Other
After hours
$150.13▲ +0.00%
Sep 11, 7:30 PM ET
Volume 163.3K
Avg Volume (10D) 190.8K
Key Metrics & Fundamentals
Market Cap
$2.16B
P/E Ratio
–
Div Yield
–%
52W Range
53.30 - 161.38
% vs 50 MA
1.04%
% vs 200 MA
25.03%
RSI-14
50.0
MACD Histogram
-0.4400
Beta (1Y vs SPY)
1.70
Free Cash Flow
-$12.85M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$19.45M
COGS
–
Operating Exp
$21.41M
Operating Income
-$21.41M
EBIT
-$21.41M
Pretax Income
-$21.87M
Net Income
-$21.87M
EPS (Diluted)
-1.52
Price & Volume History
Loading chart…
Recent News
Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer
GlobeNewswire · Sep 9, 2026 11:30 AM
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences
GlobeNewswire · Sep 2, 2026 11:30 AM
Palvella Therapeutics Completes Rolling Submission of NDA for QTORIN Rapamycin
MT Newswires · Aug 31, 2026 12:08 PM
Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
GlobeNewswire · Aug 31, 2026 11:30 AM
Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital
MarketBeat · Aug 26, 2026 5:02 PM
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands
MarketBeat · Aug 16, 2026 4:01 PM
Palvella (PVLA) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 11, 2026 5:16 PM
Is Palvella Therapeutics (PVLA) Fully Valued Ahead Of QTORIN Approval?
Simply Wall St. · Aug 8, 2026 11:10 AM
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
GlobeNewswire · Aug 5, 2026 11:30 AM
Palvella Therapeutics, Inc. Q2 2026 Earnings Call Summary
Moby · Aug 4, 2026 10:52 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See PVLA's money flow as a full page
Social Sentiment
No Reddit posts found for PVLA.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.